Gene therapy market seen reaching $46.5 billion by 2030

Allied Market Research projects the global gene therapy market will grow from $6.0 billion in 2020 to $46.5 billion by 2030, driven by chronic disease prevalence, government support and wider acceptance in cancer care. The report points to North America’s current lead, Asia-Pacific’s fastest growth and oncology as the largest and fastest-growing application segment.

Why it matters: - The gene therapy market is moving from niche to mainstream, with a projected increase of more than sevenfold by 2030. - Growth in gene therapy could reshape treatment options for cancer, chronic disease, infectious disease and blood disorders. - A bigger market could also pull in more investment, product development and healthcare infrastructure.

What happened: - Allied Market Research said the global gene therapy market was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030. - The report pegs the market at a 22.8% compound annual growth rate from 2021 to 2030. - The study covers investment opportunities, winning strategies, market size estimates, competition and emerging trends. - The company published the report on June 10, 2026.

The details: - Gene therapy uses healthy genetic material to replace partial or full defective genes in a patient’s body to treat or prevent disease progression. - The report identifies two gene therapy types: somatic gene therapy and germline gene therapy. - Chronic disease prevalence, government support and ethical acceptance of gene therapy for cancer treatment are listed as key growth drivers. - High treatment costs are identified as a market restraint. - Advanced healthcare infrastructure is described as a future opportunity for the industry. - The antigen segment held the largest share by gene type in 2020, with nearly one-fourth of the global market. - The deficiency segment is projected to post the fastest CAGR, at 26.0%, from 2021 to 2030. - The oncological disorders segment held more than two-fifths of the market in 2020. - The oncological disorders segment is also projected to grow the fastest, at 23.5% CAGR from 2021 to 2030. - North America held nearly half of global revenue in 2020. - Asia-Pacific is projected to grow the fastest, at 25.4% CAGR from 2021 to 2030. - The report links Asia-Pacific growth to chronic disease prevalence, higher healthcare spending, stronger infrastructure, reimbursement access and the presence of major market players. - Top companies listed in the report include Gilead Sciences, Orchard Therapeutics, Bristol-Myers Squibb, Adverum Biotechnologies, Amgen, Jazz Pharmaceuticals, Shenzhen SiBiono Genentech, Adaptimmune, Novartis and Shanghai Sunway Biotech. - The report also names Europe and LAMEA as additional regional markets. - A sample PDF is available here. - Purchase inquiries are available here.

Between the lines: - The forecast points to a market where oncology is still the main commercial engine. - The regional split suggests mature demand in North America and faster expansion in Asia-Pacific. - High pricing remains the biggest barrier to broader adoption, even as policy and infrastructure support improve.

What’s next: - Market growth will likely depend on whether pricing, reimbursement and access barriers ease enough to broaden use beyond early adopters. - The strongest segment momentum appears tied to cancer treatment and gene-defect applications. - Regional growth could shift further toward Asia-Pacific if healthcare investment and reimbursement continue to rise.